This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: April 22, 2010
Last updated: November 15, 2016
Last verified: August 2016
This study is designed as an extension study to the proof-of-concept trial CAIN457A2209 in patients with moderate to severe ankylosing spondylitis and aims to provide continuous treatment with AIN457 for patients in the core trial, to obtain safety and tolerability information. The study will address the evaluation of efficacy following doses of 3 mg/kg AIN457 given every 4 weeks over a period initially up to 6 months (Part 1) and based on the risk/benefit balance of AIN457 in ankylosing spondylitis a decision was taken to continue dosing for another 6 month period (Part 2).

Condition Intervention Phase
Ankylosing Spondylitis Biological: AIN457A Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Non-randomized Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti Interleukin-17 Monoclonal Antibody) in Patients With Moderate to Severe Ankylosing Spondylitis

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Safety and tolerability (Vital signs, ECG, Hematology; Blood chemistry; Urinalysis, Adverse Events, Immunogenicity) [ Time Frame: Up to 64 weeks ]

Secondary Outcome Measures:
  • Immunogenicity of AIN457 [ Time Frame: Up to 64 weeks ]
  • Total IL-17 concentration in blood at steady-state [ Time Frame: Up to 64 weeks ]
  • Pharmacokinetics of AIN457 at steady state [ Time Frame: Up to 64 weeks ]

Enrollment: 39
Study Start Date: April 2010
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AIN457 Biological: AIN457A


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A diagnosis of ankylosing spondylitis
  • Patients who took part in the core CAIN457A2209 study

Exclusion Criteria:

  • Patients for whom continued treatment with AIN457 is not considered appropriate by the treating physician.
  • Patients who were non-compliant or who demonstrated a major protocol deviation in the core CAIN457A2209 study.
  • Patients who discontinued from the core CAIN457A2209 study before Visit 14 (Week 16), and patients who completed the core study or discontinued the core study more than 2 weeks before the baseline visit.
  • Pregnant or lactating women
  • Presence of active infection
  • Positive PPD or HIV test in patients where repeated testing was deemed appropriate due to their risk profile

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01109940

United States, Arizona
Novartis Investigative Site
Paradise Valley, Arizona, United States, 85253
United States, Illinois
Novartis Investigative Site
Springfield, Illinois, United States, 62703
Novartis Investigative Site
Springfield, Illinois, United States, 62704
United States, Oklahoma
Novartis Investigative Site
Oklahoma City, Oklahoma, United States, 73112
United States, Pennsylvania
Novartis Investigative Site
Duncansville, Pennsylvania, United States, 16635
United States, Tennessee
Novartis Investigative Site
Jackson, Tennessee, United States, 38305
Novartis Investigative Site
Knoxville, Tennessee, United States, 37909
United States, Texas
Novartis Investigative Site
Benbrook, Texas, United States, 76126
United States, Washington
Novartis Investigative Site
Spokane, Washington, United States, 99204
Novartis Investigative Site
Berlin, Germany, 12203
Novartis Investigative Site
Hamburg, Germany, 22081
Novartis Investigative Site
Herne, Germany, 44625
Novartis Investigative Site
Munchen, Germany, D-80639
Novartis Investigative Site
Amsterdamn, DE, Netherlands, 1100
United Kingdom
Novartis Investigative Site
Newcastle upon Tyne, United Kingdom, NE2 4HH
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Additional Information:
Responsible Party: Novartis Pharmaceuticals Identifier: NCT01109940     History of Changes
Other Study ID Numbers: CAIN457A2209E1
Study First Received: April 22, 2010
Last Updated: November 15, 2016

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Ankylosing spondylitis
IgG1K monoclonal antibody
Interleukin -17A neutralizing

Additional relevant MeSH terms:
Spondylitis, Ankylosing
Bone Diseases, Infectious
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Joint Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on September 19, 2017